In the updated data analysis that accounted for 15 additional months of follow-up (March 2021), 4 new ILD cases were reported (15.8%, Table 1) and were classified as grade 1 (3.8%), 2 (8.7%), and 5 (2.7%).11 Guidelines and consensus statements on drug-induced ILD are available from professional congresses and societies,23,24 but these guidelines do not discuss HER2-targeted therapies. Here, ERBB2 is linked to interstitial lung disease.